CanniMed 1:20

Phase 1Small molecule

UUniversity of Saskatchewan

CanniMed 1:20 is one of 4 small molecule programs targeting Epileptic encephalopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Epileptic EncephalopathyActive, not recruiting

Epileptic EncephalopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Epileptic Encephalopathy

#DrugCompanyPhaseTrials

Namenda

FForest Laboratories

Approved

1 2

NBI-827104

Neurocrine Biosciences

Phase 2

2 3

Keppra

UCB

Preclinical

—4

CanniMed 1:20

UUniversity of Saskatchewan

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epileptic encephalopathy1 trial

Cannabidiol in Children With Refractory Epileptic Encephalopathy

Unknown status·UUniversity of Saskatchewan·Phase 1·NCT03024827·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CanniMed 1:20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CanniMed 1:20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CanniMed 1:20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Saskatchewan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Saskatchewan

CanniMed 1:20

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epileptic encephalopathy1 trial

References

Drug Info

Quick Facts

Related News